Department of Medicine, Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Vanderbilt Transplant Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Transpl Infect Dis. 2022 Dec;24(6):e13967. doi: 10.1111/tid.13967. Epub 2022 Nov 8.
Reports on outcomes following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in lung transplant recipients remain limited.
We performed a single-center, observational study of outcomes in lung transplant recipients diagnosed with SARS-CoV-2 between 5/1/2020 and 3/15/2022 that were followed for a median of 123 days. We analyzed changes in spirometry, acute lung allograft dysfunction (ALAD) incidence, hospitalization, mechanical ventilation needs, secondary infection, and survival.
In our cohort of 336 patients, 103 developed coronavirus disease (COVID) (27 pre-Delta, 20 Delta, and 56 Omicron-era). Twenty-five patients (24%) required hospitalization and 10 patients ultimately died (10%). Among 85 survivors who completed ambulatory spirometry, COVID-19 did not alter change in forced expiratory volume in 1 s (FEV ) or forced vital capacity (FVC) over time compared to the preceding 6 months. The pre-COVID FEV change was -0.05 ml/day (IQR -0.50 to 0.60) compared to -0.20 ml/day (IQR -1.40 to 0.70) post-COVID (p = .16). The pre-COVID change in FVC was 0.20 ml/day (IQR -0.60 to 0.70) compared to 0.05 ml/day (IQR -1.00 to 1.10) post-COVID (p = .76). Although the cohort overall had stable lung function, 33 patients (39%) developed ALAD or accelerated chronic lung allograft dysfunction (FEV decline >10% from pre-COVID baseline). Nine patients (35%) with ALAD recovered lung function. Within 3 months of acute COVID infection, 18 patients (17%) developed secondary infections, the majority being bacterial pneumonia. Finally, vaccination with at least two doses of mRNA vaccine was not associated with improved outcomes.
This study describes the natural history of SARS-CoV-2 infection in a large cohort of lung transplant recipients. Although one third of patients develop ALAD requiring augmented immunosuppression, infection with SARS-CoV-2 is not associated with worsening lung function.
关于严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)感染后肺移植受者结局的报告仍然有限。
我们对 2020 年 5 月 1 日至 2022 年 3 月 15 日期间诊断为 SARS-CoV-2 的肺移植受者进行了一项单中心、观察性研究,中位随访时间为 123 天。我们分析了肺功能、急性肺移植物功能障碍(ALAD)发生率、住院、机械通气需求、继发感染和生存率的变化。
在我们的 336 名患者队列中,有 103 名患有冠状病毒病(COVID)(27 名在 Delta 之前,20 名在 Delta 期间,56 名在奥密克戎时期)。25 名患者(24%)需要住院治疗,最终有 10 名患者死亡(10%)。在完成门诊肺量计检查的 85 名幸存者中,与前 6 个月相比,COVID-19 并未改变用力呼气量(FEV )或用力肺活量(FVC)的变化。与 COVID 前相比,COVID 前的 FEV 变化为-0.05ml/天(IQR-0.50 至 0.60),而 COVID 后的变化为-0.20ml/天(IQR-1.40 至 0.70)(p=0.16)。COVID 前 FVC 的变化为 0.20ml/天(IQR-0.60 至 0.70),而 COVID 后为 0.05ml/天(IQR-1.00 至 1.10)(p=0.76)。尽管总体而言,该队列的肺功能稳定,但 33 名患者(39%)发生 ALAD 或加速性慢性肺移植物功能障碍(FEV 从 COVID 前基线下降>10%)。9 名(35%)有 ALAD 的患者恢复了肺功能。在急性 COVID 感染后 3 个月内,18 名患者(17%)发生继发性感染,大多数为细菌性肺炎。最后,至少接种两剂 mRNA 疫苗与改善结局无关。
本研究描述了 SARS-CoV-2 感染在一大群肺移植受者中的自然史。尽管三分之一的患者发生需要增强免疫抑制的 ALAD,但 SARS-CoV-2 感染与肺功能恶化无关。